Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8036071004
Share Class Description:
LTS:0L35: Ordinary SharesTotal Employee Number:
835Description
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.63 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | 8.3 | |||||
Interest Coverage | 0.02 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 0.16 | |||||
Beneish M-Score | -2.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 27.2 | |||||
3-Year EBITDA Growth Rate | 3.1 | |||||
3-Year EPS without NRI Growth Rate | 10 | |||||
3-Year FCF Growth Rate | 8.3 | |||||
3-Year Book Growth Rate | 35.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -13.91 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.17 | |||||
9-Day RSI | 51.34 | |||||
14-Day RSI | 53.34 | |||||
3-1 Month Momentum % | -28.26 | |||||
6-1 Month Momentum % | -29.72 | |||||
12-1 Month Momentum % | -17.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.63 | |||||
Quick Ratio | 2.62 | |||||
Cash Ratio | 1.31 | |||||
Days Inventory | 443.73 | |||||
Days Sales Outstanding | 79.39 | |||||
Days Payable | 66.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.1 | |||||
Shareholder Yield % | 9.74 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.88 | |||||
Operating Margin % | 0.05 | |||||
Net Margin % | 2.98 | |||||
EBITDA Margin % | 5.72 | |||||
FCF Margin % | 4.96 | |||||
OCF Margin % | 8.02 | |||||
ROE % | 5.03 | |||||
ROA % | 1.89 | |||||
ROIC % | 0.04 | |||||
3-Year ROIIC % | -10.7 | |||||
ROC (Joel Greenblatt) % | 5.92 | |||||
ROCE % | 3.04 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 5.38 | |||||
PE Ratio without NRI | 14.17 | |||||
PS Ratio | 0.94 | |||||
PB Ratio | 1.32 | |||||
Price-to-Tangible-Book | 1.35 | |||||
Price-to-Free-Cash-Flow | 15.03 | |||||
Price-to-Operating-Cash-Flow | 9.94 | |||||
EV-to-EBIT | 29.7 | |||||
EV-to-Forward-EBIT | 18.68 | |||||
EV-to-EBITDA | 18.97 | |||||
EV-to-Forward-EBITDA | 12.38 | |||||
EV-to-Revenue | 1.09 | |||||
EV-to-Forward-Revenue | 1.36 | |||||
EV-to-FCF | 21.9 | |||||
Price-to-GF-Value | 0.14 | |||||
Price-to-Median-PS-Value | 0.08 | |||||
Price-to-Graham-Number | 0.92 | |||||
| Price-to-Net-Current-Asset-Value | 3.12 | |||||
Earnings Yield (Greenblatt) % | 3.37 | |||||
FCF Yield % | 5.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sarepta Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,184.184 | ||
| EPS (TTM) ($) | -0.96 | ||
| Beta | 0.0878 | ||
| 3-Year Sharpe Ratio | -0.52 | ||
| 3-Year Sortino Ratio | -0.63 | ||
| Volatility % | 52.02 | ||
| 14-Day RSI | 53.34 | ||
| 14-Day ATR ($) | 0.933674 | ||
| 20-Day SMA ($) | 18.07789 | ||
| 12-1 Month Momentum % | -17.12 | ||
| 52-Week Range ($) | 10.485 - 26 | ||
| Shares Outstanding (Mil) | 105.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sarepta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sarepta Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 112 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 23 days | ||
| Oppenheimer CNS and Neuro-Muscular Summit | 2026-06-10 | 15.90 (+2.05%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 10:40 | 15.82 (-6.64%) | ||
| General meeting for 2026 | 2026-06-04 10:00 | 16.30 (+0.25%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 08:30 | 16.84 (-3.50%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 21.55 (-2.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 21.55 (-2.00%) | ||
| Phase 1/2 Preliminary Data Readout for DM1 and FSHD Programs | 2026-03-25 08:30 | 17.68 (+1.68%) |
Show
Entries
Sarepta Therapeutics Inc Frequently Asked Questions
What is Sarepta Therapeutics Inc(LTS:0L35)'s stock price today?
The current price of LTS:0L35 is $18.59. The 52 week high of LTS:0L35 is $26.00 and 52 week low is $10.49.
When is next earnings date of Sarepta Therapeutics Inc(LTS:0L35)?
The next earnings date of Sarepta Therapeutics Inc(LTS:0L35) is 2026-08-06 Est..
Does Sarepta Therapeutics Inc(LTS:0L35) pay dividends? If so, how much?
Sarepta Therapeutics Inc(LTS:0L35) does not pay dividend.
Press Release
Articles on Sarepta Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers